Renal Denervation Insights

Published: 12 February 2021

Views:
28449
Likes:
7

Views:
28449
Likes:
7
Share:

Now Playing
Part 1 | Session 6 of 7
Radiofrequency Renal Denervation in a High-risk Population: The Verona experience
Flavio Ribichini

Up Next
6m 40s

Part 1 | Session 7 Patient Profiles for Renal Denervation
Isabella Sudano

30m 24s

Part 2 | Session 1 The Science of Radiofrequency Renal Denervation – Part 1
Andrew SP Sharp, Stefan Tunev
1h 12m 55s

Part 2 | Session 2 The Science of Radiofrequency Renal Denervation – Part 2
Andrew SP Sharp, Stefan Tunev
9m 14s

Part 2 | Session 3 TCT 2019: RF renal denervation – Prof Andrew Sharp
Andrew SP Sharp

59m 59s

Part 1 | Session 1 The Future of Hypertension Management – Renal Denervation Provides Another Treatment Option Justin E Davies, Faisal Sharif, Roland E Schmieder, Flavio Ribichini, Isabella Sudano

1h 1m 3s

Part 1 | Session 2 El futuro del manejo de la hipertensión: la denervación renal brinda otra opción de tratamiento Oriol Rodriguez, Maribel Troya

59m 14s

Part 1 | Session 3 Die Zukunft des Hypertoniemanagements – Renale Denervierung bietet eine weitere Behandlungsoption Joachim Weil, Oliver Dörr

1h 2m 27s

Part 1 | Session 4 Il futuro della gestione dell’ ipertensione - La Denervazione renale, una nuova opzione di trattamento Flavio Ribichini, Stefano Taddei

5m 47s

Part 1 | Session 5 Clinical Event Reductions in High-Risk Hypertension Patients Treated with Radiofrequency Renal Denervation Roland E Schmieder

Average (ratings)

No ratings

Your rating

Overview

Global Experts Discuss Renal Denervation as an Additional Treatment Option for Uncontrolled Hypertension

Review the evidence on radiofrequency renal denervation, including safety, efficacy and durability data and practical aspects around patient selection and management.

Medical Education Program

Patient Selection and Practical Implementation of Renal Denervation in Patients With Treatment-Resistant Hypertension

This case-based course brings together opinion leaders engaged in RDN to review the evidence, discuss trial data, and practical aspects around patient selection and management.

Click here to watch:

IME series

CME education

This educational content is supported by Medtronic.

More from this programme

Part 1

Clinical Data and Patient Identification

Global leaders share their expertise in the field of Renal Denervation. Key topics include latest RDN clinical evidence including Pivotal trial results, how to identify potential RDN patients, and the role of patient preference in hypertension management. Presented in English, Spanish, Italian, and German.

7 sessions
The Future of Hypertension Management – Renal Denervation Provides Another Treatment Option	Watch now
El futuro del manejo de la hipertensión: la denervación renal brinda otra opción de tratamiento	Watch now
Die Zukunft des Hypertoniemanagements – Renale Denervierung bietet eine weitere Behandlungsoption	Watch now
Il futuro della gestione dell’ ipertensione - La Denervazione renale, una nuova opzione di trattamento	Watch now
Clinical Event Reductions in High-Risk Hypertension Patients Treated with Radiofrequency Renal Denervation	Watch now
Radiofrequency Renal Denervation in a High-risk Population: The Verona experience	Watch now
Patient Profiles for Renal Denervation	Watch now

Part 2

Science of Radiofrequency Renal Denervation

Experts explain the mechanism of action behind radiofrequency renal denervation, including evidence demonstrating long-term safety and efficacy.

3 sessions
The Science of Radiofrequency Renal Denervation – Part 1	Watch now
The Science of Radiofrequency Renal Denervation – Part 2	Watch now
TCT 2019: RF renal denervation – Prof Andrew Sharp	Watch now

Faculty Biographies

Flavio Ribichini

Cardiologist

Prof Flavio Ribichini is a board certificated Cardiologist at the University of Turin, the Director of the School of Cardiovascular Diseases of the School of Medicine University of Verona, and Clinical Director of the Division of Cardiology of AOUI, Verona.

Prof Ribichini is an interventionalist dedicated to vascular angioplaties, valvular replacement and congenital intervention.

View full profile